• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilar Articles for the Week of July 12

Video

Here are the top 5 biosimilar articles for the week of July 12, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of July 12, 2021.

Number 5: Presentations from the European Crohn's and Colitis Organization annual meeting supported the transition to adalimumab biosimilars and provided patient acceptance data.

Number 4: In a white paper, the International Generic and Biosimilar Medicines Association (IGBA) described industry dynamics that it said affect market sustainability and patient access.

Number 3: Medicare lost out on over $2 billion in savings as adalimumab biosimilars were sidelined by patent restrictions, said investigators who recommended patent reforms.

Number 2: Bioeq signed a deal with Teva Pharmaceutical Industries to commercialize a ranibizumab biosimilar candidate (FYB201) in the European Union, Canada, Israel, and New Zealand.

Number 1: Biosimilars are launching at significant discounts to reference products and capturing increasing market share, according to a recent Amgen trends report.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Here are the top 5 biosimilar articles for the week of June 10, 2024.
Lakesha Farmer, PharmD
The Top 5 Biosimilar Articles of the Week.
Here are the top 5 biosimilar articles for the week of May 27, 2024.
Lakesha Farmer from Cencora
Here are the top 5 biosimilar articles for the week of May 20, 2024.
Here are the top 5 biosimilar articles for the week of May 13, 2024.
Jeffrey Casberg, RPh, MS.
Related Content
© 2024 MJH Life Sciences

All rights reserved.